On May 6, 2026, NASDAQ-listed Cosmos Health Inc. (COSM) announced the U.S. launch of Fort18, a men's sexual stamina supplement that becomes the company's third entry in its science-backed "18 Series" of nutraceuticals. Fort18 is formulated as a 500mg twice-daily capsule containing a proprietary blend of L-arginine, Mucuna seed extract, fenugreek seed extract, ashwagandha root extract, and artichoke leaf extract — standardized to a minimum 20% saponins and 1.5% total flavonoids. It is the first dedicated men's-wellness SKU in a portfolio that previously focused on women's metabolic and bone health under the same "18" branding.

Why It Matters

The men's sexual-stamina supplement category has been one of the messiest corners of the OTC sexual-wellness market — repeatedly hit with FDA recalls for adulterated products containing prescription PDE5 inhibitors, FTC enforcement on unsubstantiated claims, and Amazon's late-March 2026 cGMP-testing deadline that forced sellers to either prove third-party lab compliance or get delisted. Fort18's launch is a textbook example of the category cleanup playing out in real time: a NASDAQ-listed company with EU manufacturing, published clinical data, dosing matched to the studied amount, and explicit positioning against the hidden-drug supplement risk profile. Whether the science holds up under independent scrutiny is a separate question (the cited 5.1-fold endurance improvement comes from a single 60-participant study), but the regulatory and supply-chain credibility of the launch is materially different from the typical Amazon-marketplace stamina pill. For the broader men's-sexual-health vertical, Fort18 also represents the second-wave entry of pharma-credentialed players into the OTC stamina segment, joining Life Extension's Advanced Male Sexual Support (April 2026 launch) in the "fenugreek-and-fruit-extract" formulation niche. Expect further category consolidation as Hims pivots from compounded GLP-1 to specialty men's health (per the April 30 Testosterone Rx+ launch) and as the FDA's late-April Federal Register notice opens the door to TRT label expansion for low libido in idiopathic hypogonadism.

The launch is anchored to a published clinical study in the Journal of Medicinal Food (September 2020) that tested the same proprietary ingredient against placebo in 60 healthy men aged 18–60 over an 8-week randomized double-blind protocol. The reported outcome was a 5.1-fold improvement in endurance over placebo, with effects appearing as early as Week 4 and no significant changes in vital signs, blood, serum, or urine markers across the study window. Cosmos Health says every product in the 18 Series must satisfy three criteria: a proprietary ingredient backed by published research, published clinical studies supporting the intended use, and dosing consistent with the studied amount. CEO Greg Siokas framed Fort18 as "an important step in the expansion of our 18 Series into the United States" amid rising consumer demand for "products with credible scientific substantiation."

Cosmos Health is a vertically integrated pharma group founded in 2009 with pharmaceutical and nutraceutical brands, manufacturing facilities in the EU, distribution across Europe and North America, and telehealth operations through its ZipDoctor platform. The company's stock (NASDAQ: COSM) has been a small-cap turnaround story, and the U.S. men's-sexual-wellness aisle — where Hims & Hers, Ro, and BlueChew dominate the prescription side and Promescent, Life Extension Advanced Male Sexual Support, and Roman Swipes lead the OTC side — represents one of the largest TAM expansion opportunities the company has tapped.

Fort18 lands directly into the same OTC men's-stamina category that the FDA hit with three high-profile recalls in March 2026 for chocolates, honeys, and supplements containing undeclared sildenafil and tadalafil. Cosmos Health's pitch — five clinically-studied botanical ingredients, no PDE5 inhibitors, no controlled substances, no prescription required — is explicitly counter-positioned against both the recalled hidden-drug products and the prescription telehealth ecosystem. Pricing and channel partners (Amazon, GNC, CVS) had not been publicly disclosed at launch.

Sources

Update — 2026-05-07

Initial entry — story first created.